Changing MIC Breakpoints: Do Mechanisms Count
Changing MIC Breakpoints: Do Mechanisms Count Changing MIC Breakpoints: Do Mechanisms Count
Inoculum Effect • Animal studies also demonstrate an inoculum effect and adverse outcomes when cephalosporins are used to treat ESBLproducing organisms with MICs of cephalosporin in the susceptible range. 14
Efficacy of different beta-lactams against an ESBL-producing K. pneumoniae in rat IAA Model • Abscess created by intraperitoneal placement gelatin capsule containing sterile rat cecal contents, killed B. fragilis, and 1:100 dilution of ESBL-K. pneumonia (ca. 10 5 CFU) • Treatment begun by continuous infusion via left internal jugular vein 3-4 hours after placement of capsule and continued 3 days. • On day 2 and 3 blood samples were collected for determination of serum antibiotic levels • After 3 days animals were sacrificed, abdominal wall portion of abscess removed and quantitative culture performed Rice LB et al. Antimicrob Agents Chemother. 1991 Jun;35(6):1243-4. 15
- Page 1 and 2: Changing MIC Breakpoints: Do Mechan
- Page 3 and 4: • The major issue is whether the
- Page 5 and 6: CLSI Guidelines Staph spp. Table 2
- Page 7 and 8: New CLSI Guidelines 2010 • This d
- Page 9 and 10: Clinical Studies • No randomized
- Page 11 and 12: New CLSI Guidelines 2010 • Proble
- Page 13: MICs in g/ml: SHV-3 producing Citro
- Page 17 and 18: Efficacy of different beta-lactams
- Page 19 and 20: Efficacy of different beta-lactams
- Page 21 and 22: CAP Survey D-C 2007 D-19 C. freundi
- Page 23 and 24: New CLSI Guidelines 2010 • Proble
- Page 25 and 26: MIC Reproducibility • In this imp
- Page 27 and 28: Enterobacteriaceae Revised Breakpoi
- Page 29 and 30: Cephaloporin Breakpoints Following
- Page 31: New CLSI Guidelines 2010 • Proble
- Page 34 and 35: Why labs should continue to perform
- Page 36 and 37: Are the New CLSI Breakpoints the Co
- Page 38 and 39: Something to Think About • Breakp
- Page 40 and 41: Something to Think About • Antibi
- Page 42 and 43: Personalized Antibiotic Report •
- Page 44 and 45: Personalized Antibiotic Report •
- Page 46: Are the New CLSI Breakpoints the Co
Efficacy of different beta-lactams against an<br />
ESBL-producing K. pneumoniae in rat IAA Model<br />
• Abscess created by intraperitoneal placement gelatin<br />
capsule containing sterile rat cecal contents, killed B.<br />
fragilis, and 1:100 dilution of ESBL-K. pneumonia (ca.<br />
10 5 CFU)<br />
• Treatment begun by continuous infusion via left internal<br />
jugular vein 3-4 hours after placement of capsule and<br />
continued 3 days.<br />
• On day 2 and 3 blood samples were collected for<br />
determination of serum antibiotic levels<br />
• After 3 days animals were sacrificed, abdominal wall<br />
portion of abscess removed and quantitative culture<br />
performed<br />
Rice LB et al. Antimicrob Agents Chemother.<br />
1991 Jun;35(6):1243-4.<br />
15
Change language